[1]Xiong A.Randomized, Open-label, Phase III Study ofSAF-189s Versus Crizotinib in First-LineALK-Positive Advanced Non-Small Cell LungCancer (NSCLC). WCLC 2024.

[2]Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834

[3]Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47-53. Published 2024 Feb 2. doi:10.1016/j.jncc.2024.01.006.

[4]Bareschino MA, Schettino C, Rossi A, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3(2):122-133. doi:10.3978/j.issn.2072-1439.2010.12.08.

[5]Gou LY, Wu YL. Prevalence of driver mutations in non-small-cell lung cancers in the People s Republic of China. Lung Cancer (Auckl). 2014;5:1-9. Published 2014 Feb 12. doi:10.2147/LCTT.S40817.

[6]Yang JJ, Zhou J, Liu SM, et al. Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study. Respir Med. 2024;12(9):671-680. doi:10.1016/S2213-2600(24)00171-1.